Menu
Advanced
Structure search
List search
EN
CN
ES
FR
JP
KR
Wish Lists
Cart
Sign in
Sign in
Contact us
Catalog
of Screening Compounds
Screening Libraries
Building Blocks
Advanced
Structure search
List search
Homepage
>
Company
>
Media
>
Pharma News
>
2018
Pharma News, 2018
Novartis Exits Antibiotics Research, Cuts 140 Jobs in Bay Area
(Bloomberg) -- Novartis AG will shut down its antibacterial and antiviral research operations in the San Francisco Bay area and cut about 140 jobs, joining other pharmaceutical giants that hav...
Amazon and start-up Xealth are planning a pilot where doctors would 'prescribe' products to be delivered after patients leave the hospital
Amazon is talking with a start-up called Xealth and at least two hospital networks about a pilot project that would let doctors recommend bundles of medical products to their patients before they'...
Alphabet and ResMed are spinning out a start-up to solve sleep apnea, a hidden health crisis
Millions of people have sleep apnea, a potentially serious sleep disorder in which breathing repeatedly stops and starts.
Gala Therapeutics Receives FDA IDE Approval for a US Early Feasibility Study of Its RheOx(TM) System to Treat Chronic Bronchitis
MENLO PARK, Calif.
Drug giant Pfizer to split into three units, including a new hospital business
Pfizer said on Wednesday it would reorganize into three units, separating its consumer health-care business that the U.
AI system can predict side effects of drug combinations
July 10 (UPI) -- Researchers have developed an artificial intelligence system to predict potential side effects from two-drug combinations.
Sanofi closing plant in France after pollution complaint filed with government
In a series of quick actions, a conservation group accused a Sanofi plant in France of massive pollution, Sanofi moved to close the plant and pledged to address the issue and government regulators ju...
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
HERTFORDSHIRE, England and PITTSBURGH, July 9, 2018 -- (Healthcare Sales & Marketing Network) -- Mylan N.
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
SEATTLE, July 9, 2018 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp.
Orion has started a Phase III trial to develop a drug for ALS - The patient recruitment has begun
ESPOO, Finlandn I July 6, 2018 I Orion has recruited the first patients in the Phase III clinical trial (REFALS) in which orally administered levosimendan (ODM-109) is being evaluated ...
CTI Biopharma's cancer drug fails late-stage trial, shares tumble
(Reuters) - CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending its shares down 17 percent.
Species-specific activity of antibacterial drug combinations
The spread of antimicrobial resistance has become a serious public health concern, making once-treatable diseases deadly again and undermining the achievements of modern medicine.
30
31
32
33
34
35
36
37
38
0
item
s
in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Preplated libraries
Inhibitors and Approved Drugs
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Hit Follow up Support
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
Trends in discovery compounds
